Abstract 37P
Background
Atypical Ductal Hyperplasia (ADH) is a pre-malignant high-risk breast lesion, with morphological features similar to that of ductal carcinoma in situ (DCIS). The WHO diagnosis of ADH is defined as cytonuclear and architectural atypia <2mm in size. The current standard management is surgical excision, due to its reported 10-30% risk of upgrade to breast cancer. However, an increasingly observed alternative management utilizes a conservative approach with annual radiological follow up, quoting lower upgrade risks of 3-5%. Indications for conservative follow-up include low-risk patients or intial biopsy with vacuum assistance. Our primary aim is to investigate the ADH upgrade risk in a Singapore cohort, with a secondary goal of comparing upgrade cancer rates in upfront surgical management versus upgrade rates on conservative surveillance, to discuss feasibility of adopting a primarily conservative approach for the population.
Methods
A retrospective study was performed of 221 patients diagnosed with ADH between January 2013 to June 2023 in a tertiary institute. Initial biopsy histology, management approach and patient outcomes were evaluated. Outcome was measured by upgrade to early breast cancer. Odds ratio & relative risk was used to adjust for demographics, risk profile and biopsy methods.
Results
221 patients were diagnosed with ADH on biopsy, of whom 8 opted for surveillance. There was an overall upgrade risk of 31.22%, with 75.36% of upgrade histology being DCIS. Of all upgrades, 97.10% were diagnosed on upfront surgical excision after a mean period of 39 days, while 2.9% were diagnosed after a period of conservative surveillance. Of the 8 patients opting for conservative management, 1 patient received repeat biopsy and another 2 patients received surgical excision after a mean period of 268 days.
Conclusions
Our findings of a 31% upgrade risk of ADH to early breast cancer, consistent with that of reported literature, still support the case for upfront surgical excision of ADH. We recommend upfront surgical excision of ADH once discovered on initial biopsy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract